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The chimeric molecule K1 K 1P,,, comprising the two kringie do-
mains (K, and K
2 )
of tissue-type plasminogen activator ft-PA) and
the COOK-terminal region with the serine protease domain (P a) of
Urokinase-type plasminogen activator (u-PA), was previously
shown to have a 5- to 10-fold reduced clearance rate with
maintained specific thrombolytic activity, resulting in an in-
creased thrombolytic potency in animal models of venous and
arterial thrombosis.
To document the thrombolytic potential of K,K 2 Pa , the throm-
bolylic potency and fibrin specificity were studied in a combined
platelet-rich arterial eversion graft thrombosis and venous whole
blood clot model in heparinized dogs (100 U)kg bolus and 50 U/kg
per h infusion) . Dose-response effects of bolus injections of
KI K,P„ (0.032 to 0.25 mg/kg) were compared with those of
recombinant t,PA (rl-PA) and of recombinant single chain a-PA
(rscu-PA) (0.25 to 1.0 mg/kg each) in groups of five or six dogs,
each given heparin with or without the thromboxane synthase
inhibitor/prostaglandin endoperoxide receptor antagonist
ridogrel. Heparin and ridogrel in the absence of a thrombolytic
agent did not produce arterial reflow or venous clot tysis in five
dogs. Addition of K,K,P,,, rt-PA or rscu-PA resulted in a dose-
dependent induction of arterial reflow and or venous clot lysis in
Thrombolytic therapy, resulting in recanalization of oc-
cluded coronary arteries, preservation of left ventricular
function and reduction of mortality, has become a preferred
treatment for patients with acute myocardial infarction (1) .
Currently five plasminogen activators are used or are under
clinical investigation for coronary artery thrombolysis in
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the absence of systemic fibrinolytic activation and fibrinogen
breakdown .
Consistent arterial reflow required 0.063 mg/kg of K,K 2Pa and
0.5 mg/kg of rt-PA or of rscu-PA. The thrombalytic potency far
venous clot lysis, expressed as percent lysis per mg compound
administered per kg body weight, was (mean ± SEM) 750 m 160
for K,K 0P5 , 68 ± 17 for rscu-PA (p < 0.001 vs . KlK2P.) and
110 ± 29 for rt-PA (P < 0.001 vs . K,K,Pa ). The plasma clearance
rates were significantly lower for K,K 2Pu than for rscu-PA and
rt-PA, In the absence of ritlogrl, arterial reflow was significantly
slower and was followed by cyclic reocclusion and reflow ; how-
ever, venous clot lysis was unaffected. Template bleeding times
were not significantly altered in the absence but were markedly
prolonged in we presence of ridogrerei .
These results confirm and establish that, when given as a bolos
injection, K IK2Pa has an approximately 10-fold higher throm-
holytic potency for arterial and venous thrombolysis than does
rt-PA or rscu-PA . Thrombolysis with K,K0 Pa is obtained in the
absence of systemic fibrinolytic activation and fibrinogen break-
down. These properties suggest that KIKaP„ offers potenlic for
thrombolytic therapy by bolus administration in patients with
thromboembolic disease.
(J Am Coll Cardiol 1992;19.1350-9)
patients with acute myocardial infarction. These include
streptokinase, acylated plasminogen streptokinase activator
complex (APSAC, anistreplase), recombinant tissue-type
plasminogen activator (rt-PA, alteplase), recombinant sin-
gle-chain urokinase-type plasminogen activator (rscu-PA,
saruplase) and two-chain urokinase-type plasminogen acti-
vator (ricu-PA, urokinase) (1,2). In comparative studies
performed in patients with acute myocardial infarction,
fibrin-specific ri-PA and rscu-PA have been shown to be
more efficient for coronary thrombolysis than the nonfibrin-
specific streptokinase (3,4) . Still, many questions relating to
the optimal use of these compounds and to the relation
between thrombolytic efficacy and clinical benefit remain
unanswered (5).
The fibrin specificity of t-PA and scu-PA is not as
pronounced in humans as was anticipated from several
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animal models (1 .2). Furthermore. both t-PA and scu-PA
have a very short plasma half-life as a result of rapid hepatic
clearance, whereby their therapeutic use probably requires
continuous intravenous infusion of relatively large amounts
of material (50 to 100 mg), which is time consuming and
expensive
. Therefore, the search continues for thromholytic
agents with a higher thrombolytic potency and
a higher
specific thromholytic activity or a better fibrin selectivity
.
One approach to the development of improved throm-
bolytic agents might consist in the production of chimeric
proteins that contain structures harboring the enzymatic
activity of u-PA linked to structures conferring fibrin affinity
to the molecule . This approach has been investigated by
several groups, as recently reviewed
(6-8) . Some of these
compounds were shown to have retained the specific activ-
itv, catalytic efficiency and in vitro fibrinolytic potency of
u-PA (either in their single-chain or in their two-chain form)
and partially acquired the fibrin affinity and the fibrin stim-
ulation of 1-PA (9,10)
. However, combination of the fibrin-
binding domains of t-PA with the catalytic domain of scu-
PA, which endows the chimeric molecules with significant
fibrin affinity, is not associated with an increased throm-
bolytic potency in vivo
(11) .
The chimera
K,K,P,,, consisting of the two kringle do-
mains (K., and K,) of
t-PA and the serine protease domain
(P0 ) of scu-PA, was found (12) to have
. a markedly reduced
affinity for fibrin and lysine-Sepharose but an unaltered
specific activity, catalytic efficiency for plasminogen activa-
tion or fibrinolytic potency in an in vitro clot lysis system .
On in vivo evaluation in animal models of venous thrombo-
sis, K,K2P„ was found (13) to have a greatly increased
thrombolytic potency, mainly as a result of delayed clear-
ance with relatively maintained specific thrombolytic activ-
ity
. This observation led to a more detailed investigation of
the dose-response relation of K, K,P 0 , as compared with that
of rt-PA and rscu-PA, in a quantitative and reproducible
combined model for venous and arterial thrombolysis in the
dog .
Methods
Proteins and reagents. K,K2P„ was purified and charac-
terized, as described in detail elsewhere (12) . Saruplase
(commercial recombinant scu-PA) was a gift from Gru-
nenthal GmbH and Activase (commercial recombinant t-PA)
from Genentech. Ridogrel, a combined thromboxane syn-
thase inhibitor and prostaglandin endoperoxide receptor
auiagonist (i4), was a gift from the Janssen Research Foun-
dation . The thromboxane A2 analogue U46619 was obtained
from Upjohn.
Analytic methods
. Fibrinogen in plasma samples ob-
tained at baseline and at l0, 60 and 120 min was determined
with a clotting rate assay, aipha 2-anliplasmin with a chro-
mogenic substrate assay and t-PA-related, u-PA-related or
K1 K2
P, related antigen with specific enzyme-linked im-
munosorbent assays, as described elsewhere (15,16) . The
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activated partial thromboplastin times were determined by
routine laboratory assay,
Template bleeding
times were measured before and at 10 .
60 and 120 min after bolus injection of the thrombolytic
agents . The bleeding time incision was made with use of an
automated spring-loaded device (Simplate-11 . General Diag-
nostics) applied to the volar surface of the foreleg
. The
region of the incision site was washed, shaved and dried
before the first determination of bleeding time .
Platelet counting was performed on an automatic cell
counter (Sequoia Turner)
. Platelet aggregation induced with
adenosine diphosphate (ADP, approximately 5
AM
as indi-
vidually titrated), with the combination of araehidonic acid
(05 milt) and epinephrine (approximately IO AM) or with the
combination of epinephrine (10 AM) and U46619 (0
.5 p.S4)
was performed within I h after blood sampling with use of a
standard aggregometer (Chronolog)
.
Thrombolysis in Dogs With a Combined
Platelet-Rich Femoral Artery Eversion Graft
Thrombus and a Femoral Vein Blood Clot
Arterial thrombosis. The arterial thrombosis model was
modified from a rabbit femoral artery eversion graft throm-
bosis model described elsewhere (17) . Adult mongrel dogs
weighing 10 to 15 kg were premeditated with 0.25 mg/kg
body weight fluanisone intramuscularly, anesthetized with
30 mg/kg intravenous sodium pentobarbital followed by a
60-mg bolus when needed, intubated and artificially venti-
lated
. Cefacidal (I g) was given intravenously and catheters
were inserted in the left jugular vein for blood sampling and
in the brachial vein for infusion of drugs . The left carotid
artery was exposed and isolated . A 3-cm segment of the left
carotid artery was then excised, everted inside out and
immersed in physiologic saline solution. The left carotid
artery was then cannulated for continuous blood pressure
monitoring. The right femoral artery was exposed in the
inguinal region, and side branches, when present, were
ligated. The baseline blood flow in the right femoral artery
was measured with an electromagnetic flow probe (Medelad),
The everted segment from the left carotid artery was inserted
into the transsected femoral artery by end to end anastomosis
with use of 12 to 16 interrupted sutures with 7-0 nylon (DG
Atraumatic, American Cyanamid) . The microvascular clamps
occluding the proximal and distal ends of the transsected artery
were then released . Blood flow was restored to approximately
20% to 30% of baseline flow in all dogs. This was followed by
spontaneous occlusion of the everted segment graft within
approximately 30 min, which persisted for 60 min as deter-
mined by electromagnetic flow measurements .
Venous thrombosis. The venous blood clot was produced
in the left femoral vein, as previously described (18). Briefly,
the femoral vein was isolated between the inguinal ligament
and the distal bifurcation and all side branches were care-
fully ligated except for a predominant musculoculancous
branch that was cannulated
. After introduction of a woolen
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thread in the lumen, a 4-cm segment of the femoral vein was
isolated between two vessel clamps, emptied and flushed
with saline solution through the side branch catheter. The
segment was then filled with a mixture of a trace amount of
iodine-125-labeled (' 21-labeled) human fibrinogen, 0 .6 to
1 .2 ml of fresh blood and 2 U of a thrombin solution . The
venous vessel clamps were released after the right femoral
artery clot was stabilized for 60 min, and the infusion
protocol was started approximately I min later . The radio-
isotope content of the venous clot was calculated by sub-
tracting from the original amount of iodine-125 injected into
the isolated vein segment the radioisotope that was adsorbed
on the cotton swabs placed around the vein segments and
radioiodine that was washed out from the thrombus into the
blood stream, as determined I min after removal of the clamps.
Two hours after the bolus injection of thrombolytic
agents, the thrombosed segment of the femoral vein was
ligated at both sides and removed and its radioisotope
content was measured . The degree of clot lysis was deter-
mined as the residual radioactivity in the vein segment and
expressed in percent of the radioactivity originally incorpo .
rated in the clot . An isotope recovery balance was expressed
by comparing the stem of the total blood radioactivity at the
end of the experiment (multiplied by three for extravascular
distribution) and the radioactivity in the recovered thrombus
with that originally present in the clot .
Infusion protocols. All dogs received intravenous bolus
injections of heparin (100 U/kg bolus followed by infusion of
50 U/kg per h for 2 h) starting just before the release of the
right femoral artery vessel clamps. Seventy-five dogs with
stable arterial graft occlusion for 60 min were assigned to 15
study groups .
Intravenous bolus injection of K 1 K2P°
at a dose of 0.032,
0 .063, 0.125 or 0.25 mg/kg, and of n-PA or of rscu-PA at a
dose of 0 .25, 0.5 or I mg/kg was performed in groups of five
or six dogs each. All these dogs were also given an intrave-
nous bolus injection of 2 .5 mg/kg of ridogrel . a combined
thromboxane synthase inhibitor and prostaglandin endoper-
oxide receptor antagonist (14), followed by an infusion of
2 .5 mg/kg over 60 min . In addition, five dogs each were
assigned to a bolus injection of 0 .25 mg/kg of K 1 K,P
a
or
1 mg/kg ofrscu-PA and six dogs to bolus injection of I mg/kg
of rt-PA without administration of ridogrel . Five dogs used
as a control group without thrombolytic agent and three dogs
used as a control group without thrombolytic or antiplatetet
agent were studied interspersed with the active treatment
groups. The animal experiments reported in this study
conform to the guiding principles of the American Physio-
logical Society and the International Committee on Throm-
bosis and Haemostasis
(19) .
The recanalization time was taken as the time from the
injection of thrombolytic agent or placebo until reflow of the
occluded graft segment was determined with the electromag-
netic flow probe
. The blood flow was recorded continuously
during the experiments to document reocclusion or stable
reflow
. Venous clot lysis was dttermined from the residual
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radioactivity in the thrombosed segment 90 min after the
bolus injection of thrombolytic agent or placebo .
Pathologic analysis . At the end of the experiment the
dogs were killed with an overdose of pentobarbital . The
segments of the thrombosed or reperfused femoral arteries
were fixed in Bouin reagent and embedded in paraffin . The
segments were sectioned longitudinally, stained with hema-
toxylin-eosin and evaluated microscopically .
Analysis of the thrombolysis data, The results of the
arterial recanalization experiments are expressed as mean
values ± SEM . The significance of the differences between
groups was compared using the Fisher exact test for cate-
goric data or the Student t test for paired or impaired values .
A Kruskal-Wallis nonpammetric analysis of variance was
performed (20) on ranks of the ordered variable of femoral
artery patency, which ranges from 0 = persis'ent occlusion,
I = cyclic reocclusion and renew after initial recanalization
to 2 = persistent patency after initial recanalization, as
determined with the electromagnetic blood How probe . This
form of analysis of variance was selected because of the
non-gaussian distribution of the patency start variables .
The results of venous clot Ivsis were analyzed in the
following way
:
The individual values of the percent lysis (y)
versus dose in mg compound administered per kg body weight
(x) were fitted with an exponentially transformed sigmoidal
function y = 100c/(I + with use of the statistical
program GraFit (Erithacus). The mean value ± SEM of the
variables c (maximal lysis in percent), b (dose in mg com-
poundlkg body weight at which the rate of clot lysis is
maximal) and z = (ac'c5)/4 (maximal rate of lysis expressed
as percent lysis per mg compound/kg body weight) were
determined. The significance of the differences between
these variables was determined with the Student i test .
Results
Femoral Artery Eversion Graft Recanalization
and Reocciusion
Femoral artery blood flow. The results of femoral artery
blood flow measurements after the insertion of the everted
carotid artery segment into the transected femoral artery are
summarized in Table 1
. In all 75 dogs blood flow was
restored after release of the vessel clamp and stabilized at
20% to 30% of baseline . This reduced blood flow resulted
from partial constriction of the vessel at the anastomoses
and also from further reduction by intraluminal thrombus
formation
. Graft occlusion, persisting for 60 min, generally
occurred within 30 min.
Administration of 5 mg/kg of ridogrel to five heparinized
dogs did not produce recanalization
. Bolus injection of
K 1 K,P, in a dose of 0
.032 mg/kg to 0,25 mg/kg in groups of
five dogs was associated with progressively more frequent
and more rapid arterial recanalization without cyclic reoc-
clusion and reflow and with a return of blood flow to 67% of
baseline at the highest concentration
. With 0.25 to I mg/kg
bolus injection of rscu-PA or of rt-PA in combination with
JACC Vol. 19. No. 6
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Group K,K,P„
sc.-PA
n-PA o RA-
ridogrel, reflow was progressively more rapid and more
frequent without cyclic rocclusion and reflow at the highest
dose. The time course of the femoral artery recanalization in
the individual dogs is schematically represented in Figure 1
.
The results of femoral artery patency during the 2-h obser-
vation period after the start of the infusion protocol, catego-
rized as persistent occlusion, cyclic reocclusion and reflow
after initial recanalization or persistent patency after initial
reflow, are summarized in Table I .
Statistical analysis of the femoral artery blood flow data
showed no difference (p > 0 .05) in blood flow after clamp
release between groups
, to 11 (experiments with ridogrel) or
between groups 1 to 4 (experiments without ridogrel)
. At a
comparable dose of thrombolytic agent (0
.25 mglkg) blood
flow at 2 h in the experiments with ridogrel was significantly
higher for K I K,P„ than for rscu-PA (p = 0
.0001) or for rt-PA
(p = 0 .002) . At a dose of 0 .25 mg/kg, blood flow at 2 h was
significantly higher than in the control group with ridogrel
only, for K
I K2P„ (p < 0.001) and for n-PA (p < 0.001) but
not for rscu-PA . Blood flow at 2 h was not significantly
different in the groups with or without ridogret (p = 0 .1 for
0.25 mg/kg K I K2P9 , p = 0.08 for 1 .0 mg/k; rscu-PA and p =
0 .06 for 1 .0 mg/kg rt-PA) .
Rate of recanalization
. In the experiments with ridogrel,
the time to reflow decreased with increasing dose of K I K,Pn ,
rscu-PA or tt-PA . At a comparable dose of thrombolytic
agent (0
.25 mg/kg), the time to reflow in the groups with
ridogrel was significantly shorter for K,K,P, than for
rscu-PA (p = 0 .001) but was not significantly different
a .iiETAL.
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Table 1 . Effects of
K,K,P,,, rscu-PA and rt-PA on Arterial Recanalization and Reucclusion and on Venous Clot Lysis in
Hepannieed Dogs`
F- A Artery Eversioa 0=7)
	 -- Femora! Vein Clot
Wood Flow
PAencv
Thrombolylie Agent Im9kgl
1 K of bornltnel f"'.-Y)
Win,
Time
21, PO CR PP (mm"
Clot
L9sis
1%I
bob 00
Recovery
19,1
'The results represent mean values S SElt orrhe numberof experimenn indicated bti
a OIn animals with persistent occlusion-the reaow time
.-end
a value or 120 min for calculation of the mean value x SEM . Cr = cyclic reflox • :
K,K_P„
= 4PA/u-PA
chimera; PO = persistent occlusion; PP = persistent
patency; rscu-PA = recombmant single-chain urokinase-type plasmmoren act] vutor ;
n-PA = recombinenr tissue-type activator .
between K IWI, and tt-PA (p = O.ZZ). The time to reflow in
the experiments with ridogrel was significantly shorter than
that in the experiments without ridogrel for I mg/kg rscu-PA
(p < 0
.0001). but was not significantly different for
0 .25 mg/kg K,K,P„ or for I mg/kg rt-PA (p = 0
.095) .
Patency, Kruskal-Wallis analysis with patency status or-
dered in the sequence of persistent occlusion, cyclic reoc
elusion and reflow after initial recanalization and persistent
patency after initial reflow yielded the following results for
the experiments with ridogret
: The overall difference be-
tween doses within agents was significant for
K,K,P
9
(p =
0 .003), rscu-PA (p = 0.001) and rt-PA (p = 0.(02). At a
comparable dose of thrombolylic agent (0.25 mg/kg) the
patency status was significantly better for K IK,P„ than for
rscu-PA (p = 0.004) or for rt-PA (p = 0 .017), but was not
aifferenl between rt-PA and rscu-PA (p = 0 .065). The
patency status in the experiments with ridogrel was signifi-
cantly better than in the experiments without ridogrel for
0.25 mg/kg K,KiP„ (p = 0.03) and for I mg/kg rt-PA (p =
0.005), but not for I mg/kg rscu-PA (p > 0.5) .
Femora! Vein Clot Lysis and Isotope Recovery
(Table 1)
Clotlysis- In the dogs given ridogrci, dose-dependent clot
tysis was obtained with K I K,P0, rscu-PA and rt-PA ranging
between (mean t SEM) 40 t 67 and 89 -* 5% with K,K 0P,
at doses between 0.032 and 0.25 mg/kg, between 36 A 1%
and 75 ± 65o with rscu-PA at doses between 0 .25 add
With ridogrel
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Figure 1 . Schematic representation of the femoral artery patency
status in dogs treated with bolus injection of saline solution (con-
trols), K,K,P,,, rscu-PA or rt-PA, with (A) or without (B)
adminis-
tration of ridugrel
. Hatched bar = occluded artery ; open bar =
patent artery . Abbreviations as in Tale I
.
I mg/kg, and between 58
2
5% and 78 ± 5% with rt-PA at
doses between 0.25 and I mg/kg
. In the absence of throm-
bolytic agent, ridogrcl induccd 28 ± 4% venous clot lysis in
five dogs
. In the experiments without ridogrel, venous clot
lysis induced by 0.25 mg/kg K, K0
P„ (90 ± 4% ; p = 0.9), by
I mg/kg rscu-PA (80 ± 6% ; p = 0
.6) or by 1 mg/kg rt-PA (84
6%; p = 0
.5) was not significantly different from that
obtained with the same dose of thrombolytic agent combined
with ridogrel
. The calculated isotope recovery balance
ranged between 86 ± 5% and 103 ± 3% in all experimental
groups (Table 1) .
t'///A I
I
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)
I
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Analysis of data
. Fitting of the individual results (exper-
iments with ridogrel) of percent clot lysis versus mg com-
pound administered per kg body weight (thrombolvtic po-
tency) with the exponentially transformed sigmoidal
function yielded results for the variables c (maximal lysis
achieved), z (maximal rate of lysis) and b (dose at which the
maximal rate of lysis occurs) as summarized in Table 2 and
illustrated in Figure 2
. The results indicate that the throm-
bolytic potency of K,K2Pp
is significantly higher than that of
rcu-PA or rt-PA, as shown by both a higher z value (p <
0.001 vs. both rscu-PA and rt-PA) and a lower b value (p =
0.002 vs. rscu-PA and p = 0 .23 vs, rt-PA).
•
	I
Hemostasis Analysis
Bleeding time (Table 3)
. Template bleeding times mea-
sured before injection of study drugs averaged 2 to 3 min .
Bleeding times were prolonged to 20 to 30 min during
JACC Vol . 19 . Noo a
May Ml' ' 7 - 1
'The data represent mean cal - t SEM: n indicmcs the nomher of data
points used for curve faing
. fp c O
.M1 corset
K.K
.P . . ap = 11 .1.02 versus
K,K,P,, . b = dose at which the maximal rate of lysis is achieved tin mg kgl ;
mat clot lysis achieved (n %(; == maximal rare 07 clot lysis
fn
lysisper 'mgcompound dminslmedperkgWily weightotherehbrov ;adorn
as in Table l .
infusion of ridogrel and during the I-h follow-up period after
the end of the ridogreei infusion . In the experiment, without
ridogrel, bleeding times did not change significantly with
(1 .25 mg/rg K,K,P, and were somewhat prolonged with
1 mgfkg rscu-PA or it, PA . Ex vivo platelet aggregation,
induced with adenosine diphosphate (ADP), was moderately
inhibited both with ridogrel alone and with ridogrel in
combination with the plasminogen activators . However,
platelet aggregation, induced with the combination of epi-
nephrine and arachidonic acid or of epinephrine with the
thromboxane Az analogue U46619 was strongly inhibited .
The platelet count did eel change significantly in any of the
groups (data not shown) .
Coagulation assays (Table 4) . The results of fibrinogen,
alphr12-antiplasmin, activated partial thromboplastin time
and K,K0P, ;, t-PA- or u-PA-related antigen levels are sum-
Figure 2. Thrombelytic potency (percent lysis per mg compound
administered per kg body weight) of K,K,P„ ( •), rscu-PA (A) and
rt-PA )S) for venous clot lysis in dogs with combined arterial and
venous thrombosis. The data represent mean values ± SEM of the
experiments with tidogrel, as summarized in Table I
. Abbreviations
as in Table 1 .
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Table 2. Comparative Thrnmbnlytic Potereics of K, K,P,,,
rseo-PA and It-PA for venous Clot Lysis After Bolus Injection,
Combined With Ridogrel, in Dogs With Combined Arterial and
Venous Thrombosis
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marized in Table 4. At the highest dose used, K,Ka P„ did not
cause significant fibrinogen degradation or alpha 2-antiplas-
min consumption, whereas at the highest dose of rscu-PA
and rt-PA some systemic activation of tae fibrinolytic system
was observed . Activated partial thromboplastin times were
prolonged at least threefold in all experimental groups .
Plasma levels oft-PA or u-PA-related antigen 1 min after the
bolus injections increased to approximately 1 .4 tag/ml,
1 .6 µg/ml and 4 .1 µglml for a dose of 0 .25 mg/kg K,KOPa ,
rscu-PA or rt-PA, respectively (in the experiments with
ridogrel) . One hour after the bolus injection, corresponding
plasma levels were 0.65 sag/ml, 0.039 sag/mI and 0.097 sag/ml,
respectively. These data confirm the previous observation
(13; of significantly reduced plasma clearance of K,K2P„ as
compared with that of rscu-PA and rt-PA.
Pathologic Examination
Arterial patency (Table
5) .
The extent of arterial throm-
bosis was graded as occlusive thrombus, partially occlusive
thrombus, mural thrombus and patent artery. In the control
groups the occlusive thrombus occurred over the entire
length of the everted segment, with occasional but inconsis-
tent extension over a short length into the distal segment of
the femoral artery . In most of the experiments the compo .
sition of the thrombus was identified as platelet rich. Typical
examples of everted artery segments are represented in
Figure 3.
Discussion
•
The aim of the present study was to document the
•
thrombolytic potency of bolus injections of KI K2Pn , a t-PA/
Table 5
. Results of Arterial Patency as Determined by Pathologic
Analysis of the Everted Femoral Artery Segment
•
it +I +I +I +I +I +I N
I
+1+1+1
MT = mum! thrombus OT = occlusive thrombus; PA = patent artery;
PT = partially occlusive thrombus .
Flow Status
Group n OT IT MT PA
E
With ridogel
1 5 3 I 1 0
2 5 0 2 2
3 5 0 3 I
5 0 0 0
2
s o I a
m 5 5 0 0
s o I 3
5 0 1 3
9 5 2 0 J
10 5 0 1 3
E
11 6 0 2 3
Without ridogrel
1 3 3 0
5
f~
2
5 0 3
3 5 1 3 0
4 6 2
1 2 1
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Figure 3 . Longitudinal sections of the evened femoral artery segment . A. Occlusive thrombus from a dog in group 9 (sue fables)
. R Partially
occlusive thrombus from a dog in group 10 . C, Mural thrombus from a dog in group 8, D. Pmnpt artery from a dog in group 10
.
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u-PA chimera consisting of the two kringle domains of t-PA
and the serine protease domain of single-chain u-PA (12), in
a combined platelet-rich arterial thrombosis model and a
venous whole blood clot model in the dog . Dose-response
curves were obtained after single bolus injection .
Relative potency of K,KaPa, rt-PA and scu-PA . The
agents were studied alone and in combination with the
antiplatelet agent ridogrel, a potent combined thromboxane
synthose inhibitor and prostaglandin endoperoxide receptor
antagonist (14 ;. All dogs recrved anticoagulation with hep-
arin (100 U/kg bolus and 50 IJ/kg per h) resulting in a three-
to fivefold prolongation of the activated partial thromboplas-
tin time . Thereby, deposition of fibrin on the thrombus,
which would result in an apparent reduction of the lysis of
the labeled blood clot, is prevented (21) . Main end points of
arterial thrombolysis consisted of the frequency and rate of
arterial recanalization and the persistence of patency . As
previously demmrtrai,:d sir rite rabbit everted femoral artery
1I7) and in the canine everted coronary artery (22) models,
the thrombus produced in the present model is primarily
platelet rich and very resistant to dispersion with throm-
bolytic agents . Indeed, recanalization was obtained only in
one of five dogs with 0 .25 mg/kg rscu-PA and in four of five
dogs with 0.25 mglkg rt-PA ; this was consistently associated
with cyclic reocclusion and reflow . However, 0.25 mg/kg
K,K,P0 produced recanalization in a!! Of 10 dogs . although
this was only maintained in the presence of concomitant
administration of ridogrel . Higher efficacies for arterial re-
canalization were obtained with 0 .25 mg/kg K1K2P„ than
with 1 mg/kg rt-PA or rscu-PA . The administration by bolus
injection of compounds with a longer half-life such as
KIK2Pa enhances their relative thrombolytic potency as
compared with that of compounds with a short half-life such
as ri-PA or rscu-PA . We have previously documented (23)
such relative differences between K1K,Pa and scu-PA when
given by bolus injection or continuous infusion in a hamster
eiodel of pulmonary embolism .
Lysis of platelet-rich and platelet-poor clots . Engineered
pasminogen activators with an increased thrombolylic po-
tency toward erythrocyte- and fibrin-rich whole blood clots
may not necessarily constitute superior agents for the reca-
nalization of coronary arteries. These arteries not only are
frequently occluded with platelet-rich thrombus (24 .25) that
is resistant to dispersion with thrombolytic agents (17,22) but
also they are prone to reocclusion with platelet-rich throm-
bus after recanalization (26) . Indeed, the resistance to reca-
nalization attd !he tendency to reocclusion appeal to be
platelet-mediated phenomena that may be overcome with
the use of potent specific antiplatelet agents (27,28) or
thrombin inhibitors (29) .
The mechanism of the enhancing effect of K, K,P0, com-
bined with ridogrel, on the lysis of the platelet-rich thrombus
is not fully understood . It is possible that K1K,Pa induced
activation of the fibri .uolytic system dissolves the fibrin that
holds the platelet clumps together, whereas ridogrel pre-
JACC Val. 19. Na 6
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vents deposition of new platelets on the residual thrombus
and the adventitial surfaces .
Dose-dependent femoral vein clot lysis was obtained with
K1K2P,,, rscu-PA and rl-PA with a thrombolylic potency
that was approximately 10-fold higher for K1K0Pa than for
rscu-PA or rt-PA. This thrombolytic potency for venous clot
lysis was not enhanced by addition of ridogrel . Clot lysis
with K1K0Pa was achieved in the absence of significant
systemic activation of the fibrinolytic system and without
affecting the bleeding time if no ridogrel was given . The
plasma clearance of K1K,Pa after bolus injection was signif-
icantly slower than that of rscu-PA or rt-PA .
Implications. These results add to the accumulating evi-
dence that thrombolytic agents in combination with anti-
platelet agents can overcome the resistance of platelet-rich
thrombus to recanalization and prevent cyclic reocclusion
and reflow after initial recanalization . In addition, the
present results confirm that the inhibition of platelet aggre-
gation does not alter the extent of venous clot lysis, which is
primarily determined by the dose and potency of the plas-
minogen activator (30) . Bleeding complications, as wit-
nessed by the prolongation of the bleeding time with
ridogrel . remain a reason for concern, and strategies to
accelerate lysis and prevent reocclusion with less prolonga-
tion of the bleeding lime need to be further explored .
Conclusions. The present study suggests that, provided
these observations can be extrapolated to humans . K,K2Pa
may constitute a useful thrombolytic agent for coronary
artery recanalization in patients with acute myocardial in-
farction . Indeed, its del' ;•;ed clearance with relatively pre-
served specific thrombolytic activity may allow a significant
reduction of the total amount required for thrombolytic
therapy and may allow its administration by bolus injection .
W e are grateful to Mare Van Hello for the development of the exponentially
transformed signmidal function for filling of the dose-response data and to
Trees Van Coetsem, Galore Ixmmenr . Frans De Cock and Edward Demarsin
fr valuable technical assistance .
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